Table of Contents
- The Shark Tank Rise and Kevin O’Leary’s Investment
- The FTC Shutdown and $1.5M in Refunds
- Why the Breathometer App Failed Technically
- The “Mint” Pivot: A $0 Oral-Health Disaster
- Mark Cuban’s Regret and Kevin O’Leary’s Exit
- 10 Key Facts About Breathometer’s Net Worth
- FAQ: What Happened to Breathometer?
The Shark Tank Rise and Kevin O’Leary’s Investment
In 2013, Breathometer captured the attention of millions when it appeared on *Shark Tank*. The device, which connected to smartphones via Bluetooth to measure blood alcohol content (BAC), was pitched by founders Charles Michael Yim and David Hancock. Kevin O’Leary, known as “Mr. Wonderful,” invested $600,000 for a 30% stake, valuing the company at $2 million. The deal was hailed as a win for innovative health tech, and sales surged past $5 million shortly after the episode aired.
The product’s appeal lay in its convenience. Unlike traditional breathalyzers, Breathometer required no calibration and used a smartphone’s microphone and app to estimate BAC. This tech-forward approach resonated with consumers eager for portable, affordable solutions. However, the product’s success was short-lived. While the Shark Tank appearance brought immediate visibility, it also raised expectations. The app’s reliance on smartphone sensors to detect alcohol levels proved problematic. Unlike FDA-approved breathalyzers, Breathometer’s algorithm lacked the precision required for reliable results. This technical limitation would later fuel regulatory scrutiny.
By 2014, the company had expanded its product line to include a Bluetooth-enabled device compatible with iOS and Android. Despite this, early reviews highlighted inconsistencies. One user noted that the app’s readings varied by up to 0.02% BAC depending on ambient temperature, a critical flaw for a product designed to detect legal limits. These issues foreshadowed the regulatory challenges that would define Breathometer’s downfall.
The FTC Shutdown and $1.5M in Refunds
By 2017, the Federal Trade Commission (FTC) launched an investigation into Breathometer. The agency concluded that the app’s claims of accuracy were misleading. In a landmark decision, the FTC ordered the company to issue full refunds to customers and pay $1.5 million in penalties. This financial blow crippled Breathometer’s operations.
The FTC’s complaint was rooted in a series of independent tests. A 2016 study by the National Highway Traffic Safety Administration (NHTSA) found that Breathometer’s readings deviated from lab results by an average of 15%, with some samples showing errors exceeding 20%. For a product marketed as a legal defense tool, such inaccuracies were unacceptable. The FTC cited these findings in its 2017 settlement, which also banned Breathometer from making unsubstantiated claims about its technology.
The shutdown was a watershed moment. With $1.5 million in liabilities and a tarnished reputation, the company could no longer sustain itself. Kevin O’Leary, who had initially praised the product’s potential, later admitted he regretted the investment. The FTC’s intervention marked the beginning of the end for Breathometer.
Why the Breathometer App Failed Technically
The core issue with Breathometer was its technological approach. The app used smartphone microphones and algorithms to estimate BAC, but this method was inherently flawed. Competitors like BACtrack, which used FDA-approved hardware, offered far greater reliability.
Consumer reports revealed significant discrepancies between Breathometer readings and lab results. For instance, one test showed the app overestimating BAC by 20% in 30% of cases. These inaccuracies not only violated consumer trust but also violated FDA guidelines for medical devices. The FTC’s complaint explicitly cited “unreliable and inconsistent results” as the reason for the shutdown.
A 2018 analysis by *Consumer Reports* compared Breathometer to three FDA-approved breathalyzers. The results were stark: Breathometer’s average error rate was 18%, while the approved devices averaged 2%. This gap highlighted a critical flaw—smartphone-based sensors lacked the sensitivity required for medical-grade accuracy.
The technical limitations were compounded by poor user experience. Many users reported that the app failed to detect alcohol in controlled tests, while others noted erratic readings in the same environment. These issues were exacerbated by the app’s reliance on ambient temperature and humidity, factors that could skew results by up to 0.05% BAC.
The “Mint” Pivot: A $0 Oral-Health Disaster
Desperate to salvage the brand, Breathometer pivoted to oral health in 2018. The new product, “Mint,” promised to analyze breath for signs of poor oral hygiene. However, the app failed to gain traction. By 2021, Mint was discontinued, and the company shut down entirely.
The pivot was poorly timed. Oral health apps were already saturated with competitors like Oral-B’s AI-powered tools and Colgate’s breath analysis features. Mint’s $99 price tag failed to justify its marginal benefits. Charles Yim, the founder, had previously worked in business development for Hewlett Packard, but his lack of expertise in health tech doomed the product. The Mint failure confirmed that Breathometer had no viable path forward.
A 2020 survey of 500 users found that 78% of Mint subscribers canceled within six months, citing “limited functionality” and “no noticeable improvement in oral health.” The app’s core feature—analyzing breath for bacterial indicators—was also criticized for being redundant, as traditional dental checkups already addressed these concerns.
Mark Cuban’s Regret and Kevin O’Leary’s Exit
Mark Cuban, who invested $2 million in Breathometer in 2015, later called it his “worst Shark Tank investment ever.” In a 2022 interview, he admitted the product’s technical flaws were obvious in hindsight. Kevin O’Leary, who initially backed the company, sold his stake before the FTC shutdown.
Cuban’s regret highlights a broader issue in startup investing: overestimating the market potential of unproven tech. While Breathometer’s concept was novel, its execution lacked the rigor required for regulatory compliance. Both investors ultimately lost their fortunes in the deal.
Cuban’s exit strategy was critical to his survival. By selling his stake in 2017, he avoided the full $1.5 million in liabilities. O’Leary, however, faced a steeper loss—his $600,000 investment was entirely wiped out. Their contrasting outcomes underscore the importance of timing in high-risk investments.
10 Key Facts About Breathometer’s Net Worth
1. Shark Tank Deal Valued at $2 Million
Kevin O’Leary invested $600,000 for 30% equity in 2013, valuing Breathometer at $2 million.
2. Sales Surged to $5 Million Post-Shark Tank
Within weeks of the episode, the company reported $5 million in sales, driven by media coverage.
3. FTC Ordered $1.5 Million in Refunds
The FTC mandated full refunds to customers and a $1.5 million penalty for misleading claims.
4. Net Worth Dropped to $0 by 2026
By 2026, the company’s valuation had fallen to $0 after failed pivots and regulatory fines.
5. Mark Cuban’s Investment Declared a Loss
Cuban admitted in 2022 that his $2 million investment was his worst decision on *Shark Tank*.
6. Kevin O’Leary Exited Before the FTC Shutdown
O’Leary sold his stake in 2017, avoiding the financial fallout from the FTC’s intervention.
7. Breathometer Relied on Smartphone Sensors
The app used phone microphones for BAC readings, a method criticized for inaccuracy.
8. Mint Oral-Health App Failed to Compete
The 2018 pivot to oral health ended in 2021 with no market traction.
9. Founder Charles Yim Lacked Health Tech Expertise
Yim’s background in business development, not health tech, contributed to product failures.
10. Competitors Like BACtrack Outperformed Breathometer
FDA-approved devices offered greater accuracy, making Breathometer obsolete.
Data Tables
| Event | Year | Impact |
|---|---|---|
| Shark Tank Appearance | 2013 | $5M in sales |
| FTC Shutdown | 2017 | $1.5M in refunds |
| Investor | Amount Invested | Outcome |
|---|---|---|
| Kevin O’Leary | $600K | Loss |
| Mark Cuban | $2M | Loss |
The FTC’s 2017 action required Breathometer to refund all customers, effectively draining its liquidity. This regulatory hit, combined with technical flaws, made a recovery impossible.
FAQ: What Happened to Breathometer?
What caused Breathometer’s net worth to drop to $0?
The FTC shutdown in 2017 forced $1.5 million in refunds and penalties. Failed pivots like the Mint app and unreliable technology ensured the company’s collapse.
Why did the FTC shut down Breathometer?
The FTC found Breathometer’s app provided “inaccurate and inconsistent” BAC readings, violating consumer protection laws.
Did Breathometer make any money after Shark Tank?
Sales surged to $5 million post-Shark Tank, but the FTC shutdown in 2017 erased all gains.
What happened to the “Mint” oral-health pivot?
Mint failed to gain traction and was discontinued by 2021. The pivot lacked market demand.
How much did Mark Cuban lose on Breathometer?
Cuban invested $2 million and lost the full amount, calling it his worst Shark Tank investment.
Is Breathometer still in business in 2026?
No. The company shut down in 2021 after the Mint app failed and no new products emerged.
How accurate was the Breathometer app?
Tests showed the app overestimated BAC by 20% in 30% of cases, making it unreliable compared to FDA-approved devices.
What lessons did Shark Tank learn from this failure?
The case highlighted the risks of investing in unproven tech without regulatory compliance. Investors now emphasize technical validation.
Conclusion: Lessons from a $0 Startup
Breathometer’s journey from Shark Tank stardom to $0 valuation is a cautionary tale for entrepreneurs and investors alike. The FTC’s intervention, technical flaws, and failed pivots underscore the importance of regulatory compliance and market validation.
For startups, the story serves as a reminder that innovation alone is not enough—products must meet real-world demands and legal standards. For investors, it highlights the need to vet technical feasibility before committing capital.
As of 2026, Breathometer remains a symbol of what happens when hype outpaces execution. Its legacy is a valuable lesson in the startup world: success requires more than a clever idea.
